MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Neuroxelin Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Neuroxelin is a research-grade peptide blend marketed as a neuroprotective and cognitive-support formulation, combining several short peptide bioregulators of the Khavinson cytogen family (notably Cerluten/AED for cortical neuron transcriptional support and Pinealon/EDR for hippocampal protection against glutamate excitotoxicity) with adjunctive cofactors. The mechanistic premise, drawn from the broader Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology, is that ultra-short peptides cross the blood-brain barrier in trace amounts via PEPT2-mediated transport and modulate transcription of neuronal genes governing antioxidant defense, synaptic plasticity, brain-derived neurotrophic factor expression, and resistance to glutamate excitotoxicity. Researchers study Neuroxelin and its constituent peptides for age-related cognitive decline, post-stroke recovery, neurodegenerative models such as Alzheimer and Parkinson disease, and stress-induced cognitive impairment in shift-work and military contexts. Mechanistic context is provided in the Khavinson bioregulator review (PMID 21626751) and the Pinealon neuroprotection work (PMID 22500077).
Reconstitute: Add 3 mL bacteriostatic water → 16 mg/mL concentration.
Typical dose: 250–1000 mcg daily; typical dose is 500 mcg.
Easy measuring: At 16 mg/mL, 1 unit = 0.01 mL = 0.16 mg (160 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen at −20 °C; reconstituted refrigerated at 2–8 °C; use within 4 weeks of reconstitution.
Plasma half-life: Not characterized for the blend; component tripeptides are rapidly hydrolyzed in plasma with biological effects attributed to trace intact peptide reaching CNS tissue.
Typical cycle: 20 to 30 day oral course at 1 to 2 capsules once or twice daily, repeated every 4 to 6 months, frequently stacked with Endoluten in Russian neurogerontology protocols.
Regulatory status: Not approved by FDA, EMA, or other major regulators. Sold as a research compound or dietary peptide product depending on jurisdiction; no Western randomized trial data validate cognitive claims.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily over ~5 seconds[10].
Interactive Neuroxelin Syringe Calculator
Currently visualizing the 48 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 48mg dry powder in 3mL water yields 16.00 mg/mL. To evaluate a 250mcg dose, pull to 1.6 units (2 syringe ticks).
U-100 Syringe Representation
1.6 Units (2 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 500 mcg | 3 units (0.03 mL) |
| Weeks 5–8 | 750 mcg | 4.7 units (0.047 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
| Tier | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Conservative | 250 mcg | 1.6 units (0.016 mL) |
| Typical | 500 mcg | 3.1 units (0.031 mL) |
| Aggressive | 1000 mcg | 6.3 units (0.063 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 48 mg vial.
Peptide Vials (Neuroxelin, 48 mg each):
- check8 weeks (500 mcg/day): 1 vial (28 mg used; ~58% of vial)
- check12 weeks (500 mcg/day): 1 vial (42 mg used; ~88% of vial)
- check8 weeks (1000 mcg/day): 2 vials (56 mg needed)
Insulin Syringes (U-100, 30- or 50-unit recommended):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check1 vial reconstitution: 3 mL → 1 × 10 mL bottle
- check2 vials reconstitution: 6 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
Mechanism of Action (MOA)
Because Neuroxelin is a branded blend rather than a single chemically defined peptide, its mechanism of action is the superposition of the constituent peptides' pharmacology. The most commonly cited components include selank, a synthetic heptapeptide analog of the immunomodulator tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro), which modulates GABAergic and serotonergic neurotransmission and exerts anxiolytic effects in rodent and small human studies; semax, a heptapeptide derivative of ACTH(4-10) (Met-Glu-His-Phe-Pro-Gly-Pro), which upregulates BDNF and NGF expression in cortex and hippocampus and has been studied for stroke recovery and cognition; and cerebrolysin-derived peptide fragments, a porcine brain-derived hydrolysate containing low-molecular-weight neuropeptides with reported neurotrophic activity in vascular dementia and ischemic stroke [3][4][5]. Selank and semax both have plasma half-lives measured in minutes after parenteral administration, but their behavioral effects persist for hours due to triggering of downstream transcriptional cascades (BDNF, c-fos, neurotrophin pathways) that outlast peptide presence in circulation. Both are typically administered intranasally because the olfactory and trigeminal pathways provide direct nose-to-brain delivery that bypasses first-pass metabolism, and rodent studies have shown measurable accumulation in cortex and hippocampus within minutes of intranasal application. Downstream effects documented in the constituent peptide literature include increased BDNF mRNA and protein in hippocampus and cortex, reduced anxiety-like behavior in elevated plus maze and open field tests, improved performance on attention and working memory tasks in healthy volunteers, normalization of monoaminergic neurotransmitter dynamics under restraint stress, and accelerated functional recovery in animal models of ischemic stroke including reductions in penumbral neuronal loss. Cerebrolysin has been studied in human stroke trials with mixed results; some meta-analyses (Bornstein et al.) suggest modest benefit on early functional recovery, while others show no effect on long-term disability, and the heterogeneity reflects variation in patient selection, time-to-treatment, and dosing protocols across nine pooled RCTs. Common research applications include exploratory cognitive enhancement studies, adjunct treatment of post-concussive symptoms in athletes (off-label), supportive care in vascular cognitive impairment, and stress-related conditions including generalized anxiety. Because the Neuroxelin label varies by manufacturer, users must verify the specific peptides and concentrations in any given product; without disclosure of composition, dose-response and safety inference is essentially impossible. The dominant research route for the constituent peptides is intranasal administration (typically 250 to 900 mcg/day total dose divided in two or three doses), although injectable formulations exist in Russian clinical practice. No randomized double-blind placebo-controlled trial of the branded Neuroxelin blend itself has been published in Western peer-reviewed literature, so any efficacy or safety claim for the blend rests on inference from the constituent peptide datasets rather than direct evidence.
Clinical Trial Efficacy Highlights
- starSelank, one of the most commonly cited components, has been studied in small Russian clinical trials for generalized anxiety disorder with reported reductions in Hamilton Anxiety Rating Scale scores comparable to medazepam without sedation, though sample sizes and methodological rigor are limited [3].
- starSemax has been studied in Russian clinical trials for ischemic stroke recovery, with reports of improved early neurological recovery and reduced infarct volume on imaging; the strongest mechanistic data show upregulation of BDNF and NGF expression in cortex and hippocampus [4].
- starCerebrolysin meta-analyses (Bornstein et al. and others) in vascular dementia and Alzheimer disease have shown modest benefits on cognitive composite scores in some trials and no effect in others, with the heterogeneity reflecting variation in patient selection and dosing protocols [5].
- starIn rodent models of restraint stress, selank administration normalized monoaminergic neurotransmitter dynamics in hippocampus and cortex, attenuated stress-induced anxiety-like behavior, and modulated cytokine expression consistent with the proposed anti-stress mechanism [3].
- starSemax administration in animal models of cerebral ischemia reduced neuronal loss in penumbra, accelerated functional recovery, and was associated with increased expression of trophic factors BDNF and NGF in affected cortical regions [4].
- starNo randomized double-blind placebo-controlled trial of branded Neuroxelin preparations has been published; the evidence base for the blend itself is essentially anecdotal and derives from inference based on individual constituent peptide trials [1][2].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningBecause the composition of Neuroxelin preparations varies by manufacturer, side effect profiles cannot be characterized with precision; the safety profile depends on the specific peptides present and their concentrations.
- warningConstituent peptides such as selank and semax have been described as well tolerated in the published literature, with mild adverse events including transient nasal irritation, mild headache, and occasional sleep disturbance with evening dosing.
- warningCerebrolysin and other brain-derived hydrolysate components can produce hypersensitivity reactions in subjects with allergy to porcine proteins; rare cases of anaphylaxis have been reported with intravenous cerebrolysin.
- warningTheoretical concerns include modulation of monoaminergic neurotransmission that could interact with antidepressants, anxiolytics, and stimulants; concurrent use with psychotropic medications has not been systematically studied.
- warningLong-term safety data are essentially absent for the blend; constituent peptide literature is limited to short-term courses of weeks to a few months.
- warningUse in pregnancy, lactation, and pediatric populations has not been adequately studied and is not recommended.
- warningBecause Neuroxelin is not a standardized regulated product, contamination, mislabeling, and dose variability are significant additional risks; any research use should verify composition by independent analytical testing.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Neuroxelin dosage?expand_more
Dosing depends on the specific composition of the branded product. Based on the underlying selank and semax literature, intranasal administration of 250 to 900 mcg per day divided in two or three doses is common in research. Injectable formulations vary by manufacturer and lack standardized dose-response data.
How is Neuroxelin used in research protocols?expand_more
Research applications focus on cognitive enhancement studies, exploratory work in post-concussive symptoms, adjunctive support in vascular cognitive impairment, and stress-related conditions. Outcome measures typically include attention and memory batteries, anxiety and depression scales, and patient-reported wellness.
Can Neuroxelin be combined with other peptides?expand_more
In research contexts neuropeptide blends are sometimes paired with cholinergic agents, omega-3 fatty acids, and growth hormone secretagogues. No formal pharmacokinetic or pharmacodynamic interaction studies have been published, and combination use is empirical.
What are the side effects of Neuroxelin?expand_more
Side effect data for the branded blend are essentially absent. Constituent peptides (selank, semax) have been described as well tolerated with mild local irritation and occasional headache. Hypersensitivity reactions to porcine-derived components are a concern with cerebrolysin-containing formulations.
Is Neuroxelin FDA approved?expand_more
No. Neuroxelin is not approved by the FDA, EMA, or other major Western regulators in any branded form. Some constituent peptides (semax, selank, cerebrolysin) are registered in Russia and certain Eastern European jurisdictions but not in the United States, EU, or UK.
Academic References & Study Citations
Levitskaya NG, Glazova NY, Sebentsova EA, et al. Heptapeptide semax: anti-anxiety and anti-stress effects. Neurochem J. 2008;2(1-2):95-101. View Scientific Paper →
Kost NV, Sokolov OY, Gabaeva MV, et al. Selank, peptide anxiolytic of new generation: anxiolytic and antidepressant activities. Bull Exp Biol Med. 2001;132(6):1100-1102. View Scientific Paper →
Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. View Scientific Paper →
Asadullaev MN, Tananakina TP, Belousova NI. Application of Semax in the early recovery period of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(2 Suppl):23-29. View Scientific Paper →
Bornstein NM, Guekht A, Vester J, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. View Scientific Paper →
Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (clinical and electrophysiological investigation). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. View Scientific Paper →
Kolomin TA, Shadrina MI, Slominsky PA, Limborska SA, Myasoedov NF. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neurosci Med. 2013;4(4):223-229. View Scientific Paper →
Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Semax (ACTH(4-10) analogue) reduces neuronal cell death in brain regions involved in age-related neurodegeneration. Neurochem Res. 2008;33(7):1283-1287. View Scientific Paper →